OK so you thought the title of the other thread was out of date BUT unfortunately there is no way to edit thread titles.

So here is a new title

This one has got the charts at the top again & has a link to the old one.
http://www.moneyam.com/InvestorsRoom/posts.php?tid=5021

Whilst it is nice to read of Listed Companies prepared to release web-casts, it is a great shame there isn't a common-format with some "trial" presentation so we punters can align our PC's.
- - - - I have tried past Web-casts on OXB's site but had no success......

The instruction to connect 10mins before the presentation leaves little time to check your settings. (that is, even if I had nothing better to do, ahem).

Hangon: you may need to download some software. I've not had a problem with webcasts from OXB and others, and I just use a 'normal' laptop. There's usually a link on the site to whatever it is you need (e.g. Media Player or whatever).

Re webcasts: These are run by Buchanan Communications (comms company for OXB and many other minnows). The link below is from their website (http://www.buchanan.uk.com/output/). You need to input your details and then proceed - it usually works.

Registration page for webcast

Good luck!

RNS Number : 0372X
Oxford Biomedica PLC
07 August 2009








For Immediate Release


7 AUGUST 2009




OXFORD BIOMEDICA TO PRESENT AT CANACCORD ADAMS GLOBAL GROWTH CONFERENCE



Oxford, UK - 7 August 2009: Oxford BioMedica (LSE: OXB), a leading gene therapy company, is pleased to announce that John Dawson, its Chief Executive Officer, will present a company update on Tuesday, 11 August 2009 at 9.30am ET (2.30pm BST) at the Canaccord Adams 29th Annual Global Growth Conference being held in Boston, MA.

-Ends-

A sudden flurry of BUYS and the crossing of the all important 11.5 if you're into graph analysis - I'm hoping this is the start of another major rally and should see 20p soon. Maybe good news to come in the 6mth update 27AUG

RNS Number : 6531X
Oxford Biomedica PLC
19 August 2009










For Immediate Release


19 AUGUST 2009


OXFORD BIOMEDICA ANNOUNCES ACCEPTANCE OF LATE-BREAKING ABSTRACT ON TROVAX PHASE III TRIST STUDY FOR PRESENTATION AT ECCO 15-34th ESMO CONGRESS

Oxford, UK - 19 August 2009: Oxford BioMedica (LSE: OXB), a leading gene therapy company, announced today that its late-breaking abstract on the Phase III TRIST study of TroVax, its therapeutic cancer vaccine, in renal cancer has been selected for oral presentation at the joint 15th Congress of the European CanCer Organisation (ECCO) and 34th Congress of the European Society for Medical Oncology (ESMO) in Berlin, Germany. Detailed results from the most recent interim analysis of the TRIST study will be presented during a session on 'Genitourinary malignancies - Renal and Other' on 22 September 2009 from 9:00am to 11:15am CET.

The abstract is entitled 'TRIST: A randomised, double blind, placebo controlled Phase III study of MVA-5T4 in metastatic renal cancer patients'. It has been assigned an abstract number of 17LBA in the programme and abstract book, which is expected to be available at www.ecco-org.eu. A special European Journal of Cancer Supplement will also be printed and will include the TRIST abstract amongst other late-breaking and 'best' abstracts from the Congress. These abstracts will receive the highest visibility possible for an abstract presented at this conference.

The Phase III TRIST study is evaluating TroVax plus standard of care against placebo plus standard of care. The trial enrolled 733 patients with advanced or metastatic renal cancer. Despite not achieving its primary endpoint, follow-up analyses of the TRIST study have yielded valuable insights into the efficacy of TroVax, demonstrating further evidence of clinical activity and significant survival advantages to TroVax in subsets of patients.

John Dawson, Oxford BioMedica's Chief Executive Officer, said: 'We are delighted that our late-breaking abstract on the TRIST study has been accepted for presentation at the ECCO 15-34th ESMO Congress. This provides an opportunity for us to present our data at one of the world's most well-attended and high-profile cancer conferences. There are some positive findings from our recent analyses of the TRIST study and we look forward to presenting these to the oncology community.'



-Ends-

Reiteration of Oxford Biomedica by Panmure Gordon to hold...I intend to!.

Good morning allI dont think the sp will do much on until we are told of Partnership deals for ProsavinHi-8Meland Trovaxthere are supposed to be a number of interested parties in Trovaxrumoured eightsolid news on this front needed to push the sp towards 20pgiven the current 12p+ doubled since Aprilhopefully news any minute. fingers crossed.

Interims out today:

OXB - Interim results

Rodman & Renshaw Conference (Oxford Biomedica)


TIDMOXB

RNS Number : 4981Y
Oxford Biomedica PLC
04 September 2009

?


+---------------------------------------------------+--------------------------+
| For immediate release | 4 SEPTEMBER 2009 |
+---------------------------------------------------+--------------------------+






OXFORD BIOMEDICA TO PRESENT AT RODMAN & RENSHAW GLOBAL INVESTMENT CONFERENCE


Oxford, UK - 4 September 2009: Oxford BioMedica (LSE: OXB), a leading gene
therapy company, announced today that John Dawson, its Chief Executive Officer,
will present at the Rodman & Renshaw Annual Global Investment Conference to be
held on 9-11 September at the New York Palace Hotel in New York City. The
presentation is scheduled on Thursday, 10 September at 2.50pm ET (7.50pm BST).
-Ends-

Forty trades or so in the last half hour mostly buyingsmall but unusual for oxb???

it's got to break out soon...

RNS Number : 4181Z
Oxford Biomedica PLC
22 September 2009








For Immediate Release


22 SEPTEMBER 2009




OXFORD BIOMEDICA PRESENTS INTERIM RESULTS FROM PHASE III TRIST STUDY OF TROVAX IN RENAL CANCER



Oxford, UK - 22 September 2009: Oxford BioMedica (LSE: OXB), a leading gene therapy company, today announces interim results from its Phase III TRIST study of TroVax, a therapeutic cancer vaccine, in renal cancer. Although TroVax did not show a significant survival advantage compared to placebo in the total population (median survival of 20.1 months vs. 19.2 months; n = 732; p = 0.55), the survival advantage was significant in one of the predefined subsets, namely in patients with a good prognostic profile receiving interleukin-2 (IL-2) as standard of care (n = 100; p = 0.046). Additional exploratory analyses have confirmed that the anti-5T4 immune response induced by TroVax is associated with enhanced survival (p = 0.002)1, and have also identified haematological factors that were predictive of a more favourable immune response and greater survival benefit from TroVax.

The Principal UK Investigator for the study, Professor Robert Hawkins of the Christie Hospital in Manchester, is presenting the TRIST results today at the joint 15th Congress of the European CanCer Organisation (ECCO) and 34th Congress of the European Society for Medical Oncology

(ESMO) in Berlin, Germany. The abstract (#17LBA) can be viewed at http://www.ecco-org.eu.


The interim analysis of the TRIST study reflects validated survival data censored to 13 March 2009. Of 732 evaluable patients, the total reported deaths were 165 in the TroVax arm and 166 in the placebo arm. For the majority of patients (>80%), the reported cause of death was disease progression. At the cut-off date, 401 patients (55%) were still on study with a median follow-up of 13 months. The interim analysis showed that:


*

In the Intent to Treat population, estimated median survival for TroVax was 20.1 months versus 19.2 months for placebo (n = 732; p = 0.55).
*

In patients with a good prognostic profile receiving IL-2, TroVax reduced the risk of death by 46% compared to placebo (n = 100; hazard ratio (HR) = 0.54; p = 0.046). Median survival for the TroVax subset had not been reached versus 19.6 months for placebo.
*

The magnitude of the 5T4 antibody response to TroVax correlated with improved survival (p = 0.02)1, reinforcing similar observations in prior Phase II trials.
*

The anti-vector (MVA) response showed no analogous association, suggesting that survival is unrelated to patients' general health status and immune competence. This further supports the assumption that the 5T4 antibody response is clinically active.
*

Baseline platelet levels were predictive of a more favourable immune response to TroVax. The immune response was significantly more favourable in patients with 'normal' baseline platelets (n = 232) compared to 'abnormal' (n = 57), (p = 0.002)2.
*

Lower baseline platelet and monocyte levels and higher baseline haemoglobin levels were associated with increased survival benefit for TroVax versus placebo.
*

In patients with 'normal' baseline levels of these three haematological parameters, TroVax showed a promising trend in overall survival and an indicative 27% reduction in the risk of death versus placebo (n = 368; HR =0.73). The hazard ratio attained in this subset was consistent with the targeted primary endpoint for the TRIST study.
*

TroVax was well tolerated alongside standard of care and did not alter the serious or non-serious adverse event profile compared to placebo. The most common (>20%) treatment-related adverse events were pyrexia, fatigue, weight loss and nausea.

TRIST (TroVax Renal Immunotherapy Survival Trial) is a randomised Phase III study comparing TroVax to placebo, when added to first line standard of care. The trial enrolled 733 patients with advanced or metastatic renal cancer that were classified as having a good or intermediate prognosis. Patients were randomised to one of three standards of care: IL-2, interferon-alpha or sunitinib. As previously reported, vaccinations were discontinued on 11 July 2008 based on the recommendation of the study's independent Data Safety Monitoring Board, which concluded that the study would not meet its predefined primary endpoint of an improvement in overall survival.


Professor Hawkins commented on the TRIST interim analysis: 'The results presented today demonstrate that TroVax has a good safety profile and potentially improves patient survival in certain subsets of renal cancer. Importantly, the magnitude of the 5T4 immune response appears to correlate with clinical activity. The identification of baseline factors that may be predictive of a more favourable response to TroVax provides an excellent opportunity to optimise the design of future studies. Although I am disappointed that the trial did not meet its primary endpoint, I believe that TroVax is still of potential benefit to patients with cancer and I hope further studies will be initiated with more refined target populations.'


John Dawson, Oxford BioMedica's Chief Executive Officer, added: 'We are encouraged by the positive findings from our detailed analyses of the TRIST data. With these results, we aim to progress discussions with prospective partners and the oncology community in order to initiate further trials of TroVax as soon as possible. We are grateful to the clinical investigators and patients that participated in the TRIST study, whose contribution has significantly advanced our understanding of TroVax and its potential as a safe and effective therapeutic cancer vaccine.'

1. Log of ratio of 5T4 antibody titre at week 10 to baseline

2. Ratio of MVA to 5T4 antibody fold increase at week 10


-Ends

Shares in Oxford Biomedica (OXB.L) fall as much as 12 percent after investors are spooked by a clinical update which reiterates the results of a late-stage trial where the company missed its key goal, but analysts say the move is unjustified.

"This is a classic case of the market reading the headline and not understanding the real implication of the detailed data," says Ian Wainwright, managing director of life sciences specialist sales at Canaccord Adams.

He points to the positive news in the announcement, which in fact shows that the drug may still help a subset of patients.

"I'd say the sub group analysis in the trial is actually quite positive," adds Paul Cuddon, analyst at KBC Peel Hunt, reiterating his "buy" stance.

This is actually a much better result than expected and proves Trovax has some application which could be used commercially by licensing into other therapies. The initial reaction by very few was to sell but now seeing the opportunistic buying once the news has been digested. Of course the real potentially explosive news is awaited re its development of its product for Parkinsons and Prosavin could be a Blockbuster

Prosavin Update (Oxford Biomedica)


TIDMOXB

RNS Number : 7929A
Oxford Biomedica PLC
15 October 2009

?


+---------------------------------------------------+--------------------------+
| | |
+---------------------------------------------------+--------------------------+
| For Immediate Release | 15 OCTOBER 2009 |
+---------------------------------------------------+--------------------------+


OXFORD BIOMEDICA ANNOUNCES UPDATE ON PROSAVIN PHASE I/II TRIAL IN PARKINSON'S
DISEASE AND PUBLICATION OF PRECLINICAL RESULTS
Oxford, UK - 15 October 2009: Oxford BioMedica (LSE: OXB), a leading gene
therapy company, announced today new data from the ongoing Phase I/II trial of
ProSavin, its novel gene therapy for the treatment of Parkinson's disease. All
patients treated at the second dose level have completed their six-month
assessments and have shown further improvement in motor function (UPDRS III
'OFF' score). The maximum improvement was 53% and the average was 34% relative
to patients' pre-treatment motor function. The Principal Investigator, Professor
Sthane Palfi of the Henri Mondor Hospital in Paris, will present interim
results from the trial at the European Society of Gene & Cell Therapy Annual
Congress, being held in Hannover, Germany, on 21-25 November 2009.


Also announced today is the publication of pivotal preclinical studies of
ProSavin, which were conducted with collaborators from the CEA/Inserm Molecular
Imaging Research Centre (MIRCen), the University of Paris XII and the Henri
Mondor Hospital, a member of the Assistance Publique Hitaux de Paris (APHP),
in France. The findings were published in the 14 October issue of the
interdisciplinary journal, Science Translational Medicine
(http://www.sciencemag.org/). The preclinical model used for these studies
simulated severe Parkinson's disease by inducing selective degeneration of
dopamine-producing neurons, which decreased dopamine to 27% of normal
concentrations. The results showed that:


ProSavin was safe and significantly increased dopamine production from
27% to 47% of normal concentrations (p < 0.05) without the addition of L-DOPA
therapy. Overall disease severity was significantly reduced by ProSavin after
six weeks (p < 0.05)
ProSavin provided sustained recovery of motor function and behaviour over
the 12-month study, which was maintained throughout a follow-up period that
concluded after 44 months. Movement and posture were significantly improved
after two weeks (p < 0.05), reaching 77% and 85% of respective normal levels
In a study of ProSavin versus oral L-DOPA therapy, both treatments
produced a similar correction of disease symptoms. However, the ProSavin group
showed no dyskinetic side-effects, whereas L-DOPA therapy induced significant
dyskinesias after two weeks (p < 0.05)
To mimic the clinical condition of patients receiving L-DOPA therapy
after ProSavin treatment, the preclinical groups were challenged with acute
systemic administration of dopaminergic agents. Both the ProSavin arm and also a
normal healthy group showed no signs of significant dyskinesias, whereas the
control arms displayed debilitating dyskinetic movements following acute
dopaminergic challenge (p < 0.05)
Another study mimicked the Phase I/II setting of treating patients with
dyskinetic side-effects caused by long-term L-DOPA therapy. In the preclinical
model, following an extended period of L-DOPA therapy, the addition of ProSavin
maintained motor function recovery with a 44% lower daily dose of L-DOPA, which
reduced dyskinesias by up to 60%


Overall, these preclinical data suggest that ProSavin may offer significant
benefit in the clinical setting, treating the primary symptoms of Parkinson's
disease as well as reducing the severe side-effects of long-term L-DOPA therapy.
These conclusions are supported by initial data from human clinical trials.


In December 2007, Oxford BioMedica initiated a dose-escalating Phase I/II study
of ProSavin in Parkinson's disease patients experiencing reduced benefit on
L-DOPA or equivalent therapies. This first-in-man study employed a similar
neurosurgical technique to the preclinical studies for administering ProSavin
directly into a region of the brain called the putamen. Two dose levels have
been evaluated to-date in cohorts of three patients per dose. The initial dose
level (1x) was based on the safe and efficacious preclinical dose, although it
was not scaled for the larger volume of the human putamen. The second dose level
represented a cautious, small increment in dose at two-fold higher (2x) than the
first dose. At both dose levels, ProSavin was safe and well tolerated with no
serious adverse events and no evidence of immunotoxicity. All patients have
shown improved motor function and quality of life, and have maintained or
reduced their L-DOPA or equivalent medication, whereas daily doses would
normally be expected to increase over this period as the disease progresses.


Recent data from the second cohort have shown further improvement in patients'
motor function at six months. The maximum improvement was 53% and the average
was 34% relative to baseline, which would be broadly equivalent to Deep Brain
Stimulation (DBS) if confirmed in placebo-controlled studies. Even with
comparable efficacy to DBS, ProSavin would represent a significant advance,
given its simpler administration with no hardware, and its potential to enhance
patients' quality of life and suppress the complications caused by oral L-DOPA
therapy.


Despite these promising results, the excellent safety profile of ProSavin
justifies further dose escalation. Allometric scaling of the highly efficacious
preclinical dose approximates to a human dose that is five-fold higher (5x) than
the initial dose. Oxford BioMedica is seeking regulatory approval to escalate
directly to a 5x dose level using a modified administration procedure that
requires fewer needle tracks and thus reduces the surgery time. Both the study's
Data Monitoring Committee and the Company's Scientific Advisory Board support
this strategy. Enhancing the efficacy of ProSavin and reducing the surgery time
could accelerate the overall development timelines and expand the market
opportunity.


Professor Sthane Palfi commented on today's news: "The preclinical
proof-of-concept studies together with clinical data from the first two dose
levels in the Phase I/II study suggest that ProSavin may provide sustained and
meaningful benefit to patients and could reduce or eliminate the debilitating
complications associated with oral dopamine replacement therapy. In the initial
indication of moderate to late-stage Parkinson's disease, ProSavin potentially
offers significant advantages to the current alternatives of Deep Brain
Stimulation or mechanical delivery of continuous dopamine."


John Dawson, Oxford BioMedica's Chief Executive Officer, added: "The recent data
from the Phase I/II study provide further evidence that ProSavin is effective at
the current dose levels. With its excellent safety profile, we have the
opportunity to escalate to a higher dose, which could be even more effective.
This would enhance the product's value and could accelerate its development. We
look forward to the presentation of interim clinical results at the upcoming
ESGCT Congress. Furthermore, the publication of our ground-breaking preclinical
results in a leading journal raises the profile of ProSavin within the medical
community and pharmaceutical industry as we prepare for larger studies and
negotiate with prospective partners."
-Ends-

270K bid @ 13p

:-)

Just when you think it cant get any better.+67%

In at 6p this will be my next 10 bagger